<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=utf-8">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
.MsoChpDefault
	{font-size:11.0pt;
	font-family:"Arial",sans-serif;}
.MsoPapDefault
	{line-height:115%;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>Cystic Fibrosis</span></i><span lang=EN
style='font-size:12.0pt'> (CF) is a genetic disease which affects the pancreas,
lung, and other organs, which is characterized by the growth of <i>Pseudomonas
Aeruginosa </i>(PA)<i> </i>biofilms in the lungs, causing a vast number of
symptoms that affect lung ability and efficiency [1]. There are many
medications used to help the symptoms of this disease, but there are no drugs
used to kill biofilms, due to biofilms having the ability to remain resistant
to most drugs [20]. The biofilm and glue-like mucus, which is secreted by the
bacteria, cause antibiotics and other drugs to be rendered useless against
killing the bacteria [2]. Killing this barrier to the lungs, would potentially
prevent respiratory failure and the progression of CF, better than the current
treatments. Recently, a development was made in that <i>Benzoyl Peroxide </i>(BP)
and <i>Salicylic Acid </i>(SA) was able to inhibit biofilm formation and to
reduce biomass in <i>Bacterial Vaginosis</i> (BV) [3]  and<i> Escherichia Coli </i>(EC)
[9]. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>            </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>We look for information of the biofilm barrier to kill mucus and
increase the effectiveness of current CF lung medication. As seen in the BV
development, we hypothesize that if we add the drug to a carrier molecule, the
drug would attack and inhibit the biofilm barrier. In doing so, we hope to
prevent further degradation of lung function and to inhibit the effect of CF.
We plan to identify a pairing of a carrier molecule and drug to inhibit biofilm
growth and to continue to degrade the mucus and biofilm (Aim 1). We will
identify if the use of a carrier molecule delivery system increases the
efficiency of drug delivery by measuring the effect of the drug on pathogenic
biofilms associated with CF.<b> </b> (Aim 2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Aim 1</span></u></b><b><span lang=EN style='font-size:
12.0pt'>: Identify a combination of mucus permeable molecule and suitable drug
for degradation of biofilm.</span></b></p>

<ol style='margin-top:0in' start=1 type=A>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt'>Compare the benefits and the disadvantages associated with the
     mucus permeable molecule in the lungs.</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt'>Compare the benefits and the disadvantages associated with the
     drug in the body.</span></li>
</ol>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Aim 2:</span></u></b><b><span lang=EN
style='font-size:12.0pt'> Identify if the use of a carrier molecule delivery
system increases the efficiency of drug delivery by measuring the effect of the
drug on pathogenic biofilms associated with CF. </span></b></p>

<ol style='margin-top:0in' start=1 type=A>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt'>To determine if the polymeric nanoparticle delivery system allows
     for a higher percentage of the drug to be delivered to the targeted area.</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt'>To determine the drugs efficiency against pathogenic biofilms and
     the progression of CF, by simulation. </span></li>
</ol>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Background</span></u></b><span lang=EN
style='font-size:12.0pt'>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN
style='font-size:12.0pt'>Cystic Fibrosis: </span></i></b><i><span lang=EN
style='font-size:12.0pt'>Cystic Fibrosis</span></i><span lang=EN
style='font-size:12.0pt'> (CF) is a genetic disease which is expressed when
both parents have at least one copy of the gene. The <i>Cystic Fibrosis
Transmembrane Conductance Regulator</i> (CFTR) protein becomes defective when
the CFTR has a mutation present [12]. The protein is unable to move chloride to
the surface of the cell, which causes the production of mucus, due to the lack
of water present at the cell surface. This chronic illness is characterized by
the production of mucus, which causes a buildup of biofilm in the lungs and
pancreas, causing lung infections, digestion problems, inflammation, and
respiratory failure [1]. </span></p>

<p class=MsoNormal style='line-height:normal'><img width=271 height=151
src="CysticFibrosisResearchPaper.fld/image001.jpg" align=left hspace=6
vspace=6
alt="The Biofilm adhere to the surface, where the bacteria continues to proliferate, causing an irreversible , 3D figure of bacteria, known as a &quot;Biofilm.&quot; Source [6]."></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN
style='font-size:12.0pt'>Biofilm: </span></i></b><span lang=EN
style='font-size:12.0pt'>When microorganisms proliferate and continue to build
up, they create a biofilm, usually consisting of bacteria. Since the bacteria
accumulate in significant numbers, they are in close proximity, which allows
the bacteria to support each other. This allows the bacteria to exchange
substrates and share metabolic products, which allows the bacteria to use their
structure to protect the integrity of the biofilm, which are also usually made
up of different bacteria [14]. Biofilm is protected from the immune system,
antimicrobials, and some drugs [16]. The bacteria comes in contact with the
surface (<b>Figure 1</b>), where it begins to form a monolayer which eventually
produces an <i>Extracellular Matrix </i>(ECM). The ECM is also known as mucus,
which is a form of protection for the biofilm. Eventually, the bacteria
continues to grow to a 3D structure at a very significant rate, which causes
the attachment to become irreversible [6]. Biofilms can acquire resistance to
antibiotics by changing cellular structure and producing enzymes that render
the drugs ineffective [5].</span><img width=264 height=71 src=missing.gif></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN
style='font-size:12.0pt'>Biofilm in Cystic Fibrosis: </span></i></b><span
lang=EN style='font-size:12.0pt'>Chronic <i>Pseudomonas Aeruginosa </i>(PA) is
a bacterium which creates biofilm in the lungs of patients with CF. PA changes
from an acute pathogen, to a pathogen which is adapted to CF, which is due to
the polysaccharide alginate overproduction, which causes the biofilm to form
and produce a hydrogel, known as mucus [15]. The biofilm is antibiotic
resistant and phagocytosis resistant, which causes chronic inflammation, lung
damage, and lung infections [6]. Once PA forms a biofilm, the infection becomes
irreversible and is virtually impossible to destroy. Over 80% of patients with
CF are overcome by respiratory failure, which is due to the biofilm and
inflammation of the airways [7]</span></p>

<p class=MsoNormal style='line-height:normal;border:none'><b><i><span lang=EN
style='font-size:12.0pt'>BV and E. Coli Breakthrough: </span></i></b><span
lang=EN style='font-size:12.0pt'>Recently, a study was performed in which <i>Benzoyl
Peroxide (BP) </i>and<i> Salicylic Acid </i>(SA) was used to attack the biofilm
formed by <i>Gardnerella Vaginalis </i>(GV). An experiment was performed in
which concentrations of 250μ<span style='background:white'>g/mL and 125</span>μ<span
style='background:white'>g/mL of </span><i>Benzoyl Peroxide</i> and <i>Salicylic
Acid</i> were used in assays against the biofilm to see if the biofilm could be
killed or at least broken down. The results showed the in concentrations
greater than 250μ<span style='background:white'>g/mL, BP and SA were able to
inhibit the growth of GV, and that further studies will be done to see the
effects of BP and SA on other bacterial biofilms [8]. <i>Salicylic Acid</i> has
also been used in a study with </span></span></p>

<p class=MsoNormal style='line-height:normal;border:none'><i><span lang=EN
style='font-size:12.0pt;background:white'>Escherichia Coli</span></i><span
lang=EN style='font-size:12.0pt;background:white'>, where it was again proven
that SA reduces bacterial adhesion, reduces biomass, and affects the
development of the biofilms structure [9].</span></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Experimental Design:</span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Aim 1: </span></u></b><b><span lang=EN
style='font-size:12.0pt'> Identify a combination of mucus permeable molecule
and suitable drug for degradation of biofilm. </span></b><span lang=EN
style='font-size:12.0pt'>It is known that there are many different biomaterials
available to transport drugs through various body systems, allowing for the
drug to reach the targeted destination. Finding the best biomaterial for this
drug delivery application, and pairing it with a drug to help CF, may allow for
a more suitable treatment. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Aim 1A: </span></u></b><b><span lang=EN
style='font-size:12.0pt'>Compare the benefits and the disadvantages associated
with the mucus permeable molecule in the lungs. </span></b><span lang=EN
style='font-size:12.0pt'>First, we need to identify different biomaterials that
are suitable options for drug delivery. Each identified biomaterial will be
tested on multiple criteria aspects, where they will be ranked from most
effective (higher number) to least effective (lower number). The biomaterial
with the highest number will be named the most effective biomaterial for this
experiment. The three different biomaterials that will be tested are: <i>Polymeric
Nanoparticles, Micelles, and Dendrimers </i>[13]. The list of test criteria
includes, but is not limited to:</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>The transportation rate to the lungs</span></i><span
lang=EN style='font-size:12.0pt'>: the different biomaterials will be dyed
using <i>Coumarin 6</i> (fluorescent dye), which will allow us to image the
particles at various times, allowing for the transportation rate to be
calculated. The biomaterials will be injected into mice, where the
microparticles will be imaged and quantified frequently, allowing for the
fastest biomaterial to enter the bloodstream and diffuse into the lungs [10]. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN
style='font-size:12.0pt'>The ability to penetrate the mucus</span></i><span
lang=EN style='font-size:12.0pt'>: the different biomaterials will again be
dyed using <i>Coumarin 6</i>, but they will be injected into a collected mucus
gel. The biomaterials should be tested in two different collected mucus:  <i>Pseudomonas
Aeruginosa</i> and <i>Gardnerella Vaginalis</i>, allowing us to see if there
are any differences in mucus penetration. The fluorescent biomaterials will be
imaged frequently to see the process of penetration into the mucus.
Alternatively, we can use confocal microscopy (this microscopy allows us to
produce high quality images) to do this trial as well [21]. This process will
also be timed, allowing us to see which biomaterial can penetrate the mucus in
the least amount of time, but also shows us which biomaterial penetrate the
mucus most efficiently [10]. </span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>The duration of Bioadhesivity</span></i><span
lang=EN style='font-size:12.0pt'>: the different biomaterials will be filled
with fluorescent <i>Bovine Serum Albumin</i> (BSA), and then they will be
placed on the <i>Pseudomonas Aeruginosa</i> biofilm, where the bioadhesive will
be measured. There will be at least three trials for each of the different
biomaterials, allowing us to see if they can remain adhered after a short
duration of time (.5-1 hour), a medium duration (2-3 hours), and a long
duration (6+ hours). After the time duration is up, we will attempt to wash the
biomaterial off the surface of the biofilm, to allow us to see which
biomaterials remained adhered and which did not [10].</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Aim 1B: </span></u></b><b><span lang=EN
style='font-size:12.0pt'>Compare the benefits and the disadvantages associated
with the drug in the body. </span></b><span lang=EN style='font-size:12.0pt'>We
are looking for the best drug to combat biofilms, which will prevent mucus,
therefore helping patients with CF. It is important we know how effective or
ineffective this drug will be against biofilms. We will use many tests to see
how this drug affects the user, which includes, but is not limited to:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>The ability to attack the biofilm, but not
negatively affect the body</span></i><span lang=EN style='font-size:12.0pt'>:
The purpose of this drug is to attack the biofilm and prevent further growth of
it. The drug needs to be able to make it to the lungs, where it then needs to
be able to attack biofilms such as <i>Pseudomonas Aeruginosa</i> and <i>Gardnerella
Vaginalis</i>. It is important that the drug is able to attack the biofilm, but
minimize the damage to the rest of the lungs and the body. We can test if the
drug is effective against biofilms by using <i>Coumarin 6</i>, allowing us to
continuously image this process, which allows us to visually see how this drug
affects the biofilm, while at the same time, watching to see how the drug
affects the lungs and the rest of the body. This stage of testing may take a
while due to testing many different drugs and comparing their results, but we
want to focus on testing with BP and SA against <i>Pseudomonas Aeruginosa </i>due
to the results of the BV experiments.</span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Aim 2: </span></u></b><b><span lang=EN
style='font-size:12.0pt'>Identify if the use of a carrier molecule delivery
system increases the efficiency of drug delivery by measuring the effect of the
drug on pathogenic biofilms associated with CF. </span></b><span lang=EN
style='font-size:12.0pt'>We believe that a carrier molecule delivery system
will increase the efficiency of the drug against the biofilms in CF affected
lungs. We hypothesize that the drug will be delivered more efficiently,
allowing for a larger percentage of the drug to be delivered to the targeted
area. </span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Aim 2A: </span></u></b><b><span lang=EN
style='font-size:12.0pt'>To determine if the carrier molecule delivery system
allows for a higher percentage of the drug to be delivered to the targeted
area. </span></b><span lang=EN style='font-size:12.0pt'>We believe that using a
carrier molecule delivery system will be more effective against biofilms than
antibiotics are. The biofilm can become resistant to the antibiotics, and
antibiotics offer more side effects due to a larger amount of the drug
accidently being delivered to the non-targeted area. </span></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>Percent of the drug that is delivered to the
targeted area</span></i><span lang=EN style='font-size:12.0pt'>: To test how
much of the drug is being delivered to the targeted area by using <i>Coumarin 6
</i>to dye the drug/carrier, allowing us to image the body continuously. This
will allow us to track where the drug is ending up, allowing us to see if a
significant amount of the drug is being delivered to the targeted area.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Aim 2B: </span></u></b><b><span lang=EN
style='font-size:12.0pt'>To determine the drugs efficiency against pathogenic
biofilms and the progression of CF, by simulation. </span></b><span lang=EN
style='font-size:12.0pt'>The goal of this experiment is to delay the
progression of CF, allowing for the patient to live a longer life with fewer
symptoms of CF. In order to determine if the drugs are efficient, we need to
test multiple aspects, which includes, but is not limited to:</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>The Ability to Damage the Biofilm and Inhibit
Growth</span></i><span lang=EN style='font-size:12.0pt'>: The purpose of this
drug is to destroy a majority of the biofilm and prevent further growth of it.
This will be tested by comparing the size of the biofilm, to see if the biomass
has decreased by the end of this trial. We can also test if the drug is
effective against biofilms by using <i>Coumarin 6</i>, allowing us to
continuously image this process, to allow us to visualize how this drug affects
the biofilm. Specifically, we want to test BP and SA against <i>Pseudomonas
Aeruginosa </i>due to the results of the BV experiments.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='text-indent:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt'>The Progression of CF</span></i><span lang=EN
style='font-size:12.0pt'>: To measure the progression of CF, we can take a look
at how the biofilm has been affected by the drug, it will get smaller due to
bacterial necrosis, or it will get larger due to bacterial proliferation. The patients’
health will begin to worsen over time if the biofilm is not dying off. This
experiment will take a long period of time, because we have to look at the long-term
effects as well as the short term effects. We specifically want to test BP and
SA against <i>Pseudomonas Aeruginosa </i>due to the results of the BV
experiments.</span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'>Significance:</span></u></b><span lang=EN
style='font-size:12.0pt'> We are fortunate to be living in an era where
technological advances are allowing humans to live in a better state of health,
for much longer. Unfortunately, CF still has no cure, causing thousands of
people to suffer each year [17].<i> Cystic Fibrosis </i>is typically diagnosed
as a child, allowing the averaging a life expectancy of 37.5 years [11], with
over 30,000 people affected in the United States alone [1]. The current drugs
are inhalation drugs to allow for higher pulmonary concentrations, but there
are limitations due to the bronchial obstructions [18]. It has been tested and
shown that nanoparticle drug delivery systems are better at eradicating the
biofilm layer, showing that particle drug delivery systems are the future of CF
[19]. If we find a drug that can attack and inhibit the biofilm, we may be able
to help those with CF, allowing them to live a longer life, in less pain.  <i>Benzoyl
Peroxide</i> and <i>Salicylic Acid </i>have had promising results in other
trials, making those drugs more viable contestants to help battle the biofilm
in CF.</span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN
style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><u><span
lang=EN style='font-size:12.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN style='font-size:12.0pt'>Works Cited:</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[1] About Cystic Fibrosis. (n.d.). Retrieved December 5,
2019, from https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/.</span><span
lang=EN style='font-size:12.0pt'>  </span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[2] Donlan, &amp; M., R. (2001, October 15). Biofilm
Formation: A Clinically Relevant Microbiological Process. Retrieved December 5,
2019, from </span><span lang=EN><a
href="https://academic.oup.com/cid/article/33/8/1387/347551"><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#1155CC;
background:white'>https://academic.oup.com/cid/article/33/8/1387/347551</span></a></span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman",serif;color:#333333;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[3] Algburi, A., Zehm, S., Netrebov, V., Weeks, R.,
Zubovskiy, K., &amp; Chikindas, M. L. (2018, July 2). Benzoyl Peroxide Inhibits
Quorum Sensing and Biofilm Formation by <i>Gardnerella vaginalis</i>14018.
Retrieved December 6, 2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051117/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[4] Høiby, N., Ciofu, O., &amp; Bjarnsholt, T. (2010,
November). Pseudomonas aeruginosa biofilms in cystic fibrosis. Retrieved
December 6, 2019, from https://www.ncbi.nlm.nih.gov/pubmed/21133688.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[5] Hughes, G., &amp; Webber, M. A. (2017, July). Novel
approaches to the treatment of bacterial biofilm infections. Retrieved December
6, 2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481657/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[6] Hollmann, B. (n.d.). Biofilms and their role in
pathogenesis. Retrieved December 6, 2019, from
https://www.immunology.org/public-information/bitesized-immunology/pathogens-and-disease/biofilms-and-their-role-in.</span><span
lang=EN style='font-size:12.0pt'>   </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[7] Bhagirath, A. Y., Li, Y., Somayajula, D., Dadashi, M.,
Badr, S., &amp; Duan, K. (2016, December 5). Cystic fibrosis lung environment
and Pseudomonas aeruginosa infection. Retrieved December 6, 2019, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139081/.</span><span lang=EN
style='font-size:12.0pt'> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[8] Algburi, Ammar, Zehm, Saskia, Netrebov, Richard, … L., M.
(2018, July 2). Benzoyl Peroxide Inhibits Quorum Sensing and Biofilm Formation
by Gardnerella vaginalis 14018. Retrieved December 6, 2019, from
https://www.hindawi.com/journals/idog/2018/1426109/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[9] Cattò, C., Grazioso, G., Dell'Orto, S., Gelain, A.,
Villa, S., Marzano, V., … Forlani, F. (2017, March). The response of
Escherichia coli biofilm to salicylic acid. Retrieved December 6, 2019, from
https://www.ncbi.nlm.nih.gov/pubmed/28270055.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[10] Lock, J. Y., Carlson, T. L., &amp; Carrier, R. L. (2018,
January 15). Mucus models to evaluate the diffusion of drugs and particles.
Retrieved December 6, 2019, from </span><span lang=EN><a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463479/"><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#1155CC;
background:white'>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463479/</span></a></span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman",serif;color:#333333;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[11] Henderson, W. (2019, January 8). Life Expectancy When
You're Living With Cystic Fibrosis. Retrieved December 6, 2019, from
https://cysticfibrosisnewstoday.com/2017/05/24/living-cf-life-expectancy/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[12] Lyczak, J. B., Cannon, C. L., &amp; Pier, G. B. (2002,
April). Lung infections associated with cystic fibrosis. Retrieved December 6,
2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC118069/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[13] Fernández Fernández, E., Santos-Carballal, B., de Santi,
C., Ramsey, J. M., MacLoughlin, R., Cryan, S.-A., &amp; Greene, C. M. (2018,
January 13). Biopolymer-Based Nanoparticles for Cystic Fibrosis Lung Gene
Therapy Studies. Retrieved December 7, 2019, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793620/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[14] Billings, N., Birjiniuk, A., Samad, T. S., Doyle, P. S.,
&amp; Ribbeck, K. (2015, February). Material properties of biofilms-a review of
methods for understanding permeability and mechanics. Retrieved December 7,
2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504244/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[15] Lock, J. Y., Carlson, T. L., &amp; Carrier, R. L. (2018,
January 15). Mucus models to evaluate the diffusion of drugs and particles.
Retrieved December 7, 2019, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463479/.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[16] Matsui, H., Wagner, V. E., Hill, D. B., Schwab, U. E.,
Rogers, T. D., Button, B., … Boucher, R. C. (2006, November 28). A physical
linkage between cystic fibrosis airway surface dehydration and Pseudomonas
aeruginosa biofilms. Retrieved December 7, 2019, from
https://www.ncbi.nlm.nih.gov/pubmed/17116883.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[17] Milla, C. (2019, November 26). Asking the Expert: Treating
Cystic Fibrosis. Retrieved December 8, 2019, from
https://www.healthline.com/health/cystic-fibrosis/ask-the-expert-treating-cf#1.</span><span
lang=EN style='font-size:12.0pt'> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[18] Klinger-Strobel, M., Lautenschläger, C., Fischer, D.,
Mainz, J. G., Bruns, T., Tuchscherr, L., … Makarewicz, O. (2015, August).
Aspects of pulmonary drug delivery strategies for infections in cystic
fibrosis--where do we stand? Retrieved December 8, 2019, from
https://www.ncbi.nlm.nih.gov/pubmed/25642831.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[19] Demetre, D. C. (2018, March 13). Optimising Cystic Fibrosis
Treatment Using Nanotechnology. Retrieved December 8, 2019, from </span><span
lang=EN><a href="https://sciencebeta.com/cystic-fibrosis-nanotechnology/"><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#1155CC;
background:white'>https://sciencebeta.com/cystic-fibrosis-nanotechnology/</span></a></span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>.</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[20] Singh, S., Singh, S. K., Chowdhury, I., &amp; Singh, R.
(2017, April 28). Understanding the Mechanism of Bacterial Biofilms Resistance
to Antimicrobial Agents. Retrieved December 8, 2019, from </span><span lang=EN><a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427689/"><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#1155CC;
background:white'>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427689/</span></a></span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>.</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman",serif;color:#333333;
background:white'>[21] Rigby, P J, and R G Goldie. “Confocal Microscopy in
Biomedical Research.” <i>Croatian Medical Journal</i>, U.S. National Library of
Medicine, Sept. 1999, Retrieved December 9, 2019, https://www.ncbi.nlm.nih.gov/pubmed/10411961.</span></p>

<p class=MsoNormal><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN>&nbsp;</span></p>

</div>

</body>

</html>
